News

The phase 2/3 EVEREST study of zorifertinib for patients with advanced EGFR-mutated non–small cell lung cancer with central nervous system metastases elicited significant efficacy and comparable safety to other tyrosine kinase inhibitors in this indication.

The Guardant360 CDx, which will identify patients with advanced or metastatic breast cancer who have ESR1 mutations and may benefit from elacestrant, is the fifth test to be approved by the FDA and first for patients with breast cancer.

Erika P. Hamilton, MD, discusses the updated safety analysis of the DESTINY-Breast03 trial and the patients who were enrolled in the study.

Adding CTX-009 to paclitaxel generated promising responses for patients with advanced biliary tract cancer when given in the second- and third-line settings.

David O’Malley, MD, discusses the mechanism of action of ubamatamab as well as findings from a phase 1 trial evaluating the agent in patients with recurrent ovarian cancer.

An investigational immunotherapy triplet combination is showing promise for the treatment of advanced solid tumors. Recruitment for the phase 2 study continues.

Elacestrant has recieved FDA approval for the treatment of patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.

Based on findings from the phase 1/2 BRUIN trial, pirtobrutinib has been approved by the FDA for patients with relapsed/refractory mantle cell lymphoma.

Cilta-cel improved progression-free survival in relapsed/refractory multiple myeloma, according to findings from the first prespecified interim analysis of the phase 3 CARTITUDE-4 study.

Tamibarotene has received fast track designation from the FDA for use in patients with higher-risk myelodysplastic syndrome. The agent is being further evaluated in the phase 3 SELECT MDS-1 trial.

Rachna T. Shroff, MD, MS, FASCO discussed the findings from SWOG 1815 and next steps for improving upon treatment with gemcitabine and cisplatin in biliary tract cancer.

Jennifer R. Brown, MD, PhD, discusses the mechanism of action of zanubrutinib and how it differs from other Bruton’s tyrosine kinase inhibitors.

Results from the phase 3 PEARLS/KEYNOTE-091 trial have led to the FDA approval of adjuvant pembrolizumab for the treatment fully resected NSCLC.

Results from the CRC-PREVENT trial of a noninvasive diagnostic screening test have led to the submission of a premarket approval application to the FDA for patients with colorectal cancer and advanced adenomas.

With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.

The NCCN has recognized the importance of hearing loss in pediatric patients and therefore, added Pedmark to their adolescent and young adult oncology guidelines.

Topline results from the phase 2 TRANSCEND CLL 004 trial hint that lisocabtagene maraleucel may be active in relapsed or refractory chronic lymphocytic leukemia.

Tanios Bekaii-Saab, MD, FACP, discusses background that led to the start of the MOUNTAINEER-03 trial.

According to topline findings of the phase 3 KEYNOTE-966 trial, pembrolizumab in combination with gemcitabine and cisplatin led to an improvement in overall survival for patients with biliary tract cancer.

According to experts, results from the INTRIGUE study have shown the utility of ctDNA next-generation sequencing for patients with advanced gastrointestinal stromal tumor.

Phase 2 FOENIX-CCA2 study results further confirm the safety and efficacy of futibatinib for the treatment of previously treated patients with advanced/metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

In an interview with Targeted Oncology, Carolyn Owen, MD, discussed findings from the GLOW study of elderly/unfit patients with chronic lymphocytic leukemia that were presented at SOHO 2022.

Matthew Ingham, MD, discusses some of the most recent clinical updates in the sarcoma space.

Following positive data from the phase 1 ReSPECT-GBM trial, the first patient has been dosed with rhenium (186Re) obisbemeda in the phase 2 portion.

In an interview with Targeted Oncology, Thomas Flaig, MD, further discussed the updates to the 2022 NCCN guidelines for patients with bladder cancer and explained how the field has evolved over the past few years.

In an interview with Targeted Oncology, Melanie Goldfarb, MD, MSc, FACS, FACE, highlighted the importance of long-term survivorship care and the quality-of-life aspects of patients with thyroid cancer.

A speedy FDA review of the approval application for avapritinib for indolent systemic mastocytosis has commenced.

An investigational new drug application for IMPT-314 has been cleared by the FDA. A phase 1/2 trial investigating the agent will be initiated in early 2023.